Atopix Therapeutics Limited is a clinical stage biotechnology company developing novel treatments for Th2-mediated eosinophilic asthma. The company is developing a novel class of oral anti-Th2 therapies, called CRTH2 antagonists. Our lead candidate, OC459, is currently being studied in a Phase 2 proof-of-concept study to evaluate the effect of OC459 in patients with severe asthma who have persistent airway eosinophilia, despite treatment with high doses of inhaled corticosteroids; and a Phase 2a study of the response of asthmatics treated with OC459 to rhinovirus infection (common cold); and a Phase 3 clinical trial of patients with moderate persistent eosinophilic asthma in Russia. Our second cadidate, ATX2417, is undergoing a Phase 1 human safety study.
Type
Private
HQ
Milton, GB
Founded
2012
Atopix was founded in 2012 and is headquartered in Milton, GB

Atopix Locations

Milton, GB

Atopix Metrics

Atopix Summary

Founding Date

2012

Total Funding

$5.07 M

Latest funding size

$5.07 M

Time since last funding

over 1 year

Investors

We estimate that Atopix's latest funding round in July 2015 was $5.07 M. In total, Atopix has raised $5.07 M

Atopix Company Life

You may also be interested in